STOCK TITAN

Celldex Therapeutics Inc. - CLDX STOCK NEWS

Welcome to our dedicated news page for Celldex Therapeutics (Ticker: CLDX), a resource for investors and traders seeking the latest updates and insights on Celldex Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Celldex Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Celldex Therapeutics's position in the market.

Rhea-AI Summary
Celldex Therapeutics has announced the dosing of the first patient in its Phase 2 study of barzolvolimab in eosinophilic esophagitis (EoE). The study aims to evaluate the efficacy and safety of the drug in patients with active EoE. Barzolvolimab is a monoclonal antibody that targets mast cells, which are believed to play a role in the disease. The study will include approximately 60 clinical trial centers across 8 countries.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.85%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Celldex Therapeutics, Inc. (NASDAQ:CLDX) will present data from its barzolvolimab program at the European Academy of Allergy and Clinical Immunology Annual Congress 2023. The presentations will showcase the clinical activity of barzolvolimab in chronic spontaneous urticaria and antihistamine refractory cholinergic urticaria. The sessions will be held on June 10, 2023, and will be presented by renowned dermatologists and allergy experts.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.16%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.3%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.99%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.26%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.68%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.39%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.51%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Celldex Therapeutics Inc.

Nasdaq:CLDX

CLDX Rankings

CLDX Stock Data

2.58B
52.74M
0.35%
96.8%
9.98%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
US
Hampton

About CLDX

celldex is developing targeted therapeutics to address devastating diseases for which available treatments are inadequate. our pipeline is built from a proprietary portfolio of antibodies and immunomodulators used alone and in strategic combinations to create novel, disease-specific therapies that induce, enhance or suppress the body's immune response. celldex therapeutics (nasdaq: cldx) was founded based on a fundamental scientific belief that harnessing the power of the immune system would break significant barriers in drug development for a host of devastating diseases. the company's pipeline is comprised of therapeutic antibodies, antibody drug conjugates, immune system modulators and vaccines that we believe have a higher probability of success because they are targeted to specific patient populations with high unmet medical need whose diseases express specific markers, including many underserved or completely un-served orphan indications. this has created a leading pipeline in im